The t:slim X2™ insulin pump with Control-IQ™ technology can be used as a stand alone pump, or can be integrated with the Dexcom G7 or G6 continuous glucose monitoring (CGM)† system to activate the predictive insulin delivery technology.
The Control‑IQ advanced hybrid closed-loop technology makes it easier by using Dexcom CGM values to predict glucose levels 30 minutes ahead and automatically adjusts basal insulin every 5 minutes, to help increase time in range.1
Designed to help lighten the burden of diabetes management and offer more time in a healthy glucose level range, making it easier to live with Type 1 diabetes.
†CGM sold separately
Working with you 24/7 to help you live more freely
- Simplify your routine with zero fingerpricks* and no multiple daily injections
- Experience more than 90% time in range overnight¶,2
- Discreet, modern and simple to learn
- 97% said it’s easy to use3
Worry less about your diabetes
- Automatically predicts and helps prevent highs and lows^
Now powered by Dexcom’s most accurate sensor4
- The only insulin pump connected to Dexcom G7 CGM†
*If your glucose alerts and readings from Dexcom G7 do not match symptoms or expectations use a blood glucose meter to make diabetes treatment decisions.
The t:slim X2 insulin pumps, consumables and Dexcom CGM systems are fully funded by Pharmac for New Zelanders with Type 1 diabetes.
To determine if this pump is suitable for you, please consult your healthcare professional. For integration with Dexcom G7, you need to upgrade to the t:slim X2 insulin pump with Control-IQ technology (version 7.7 or later), as the Basal-IQ technology is compatible with Dexcom G6.
After starting with the t:slim X2 insulin pump with Basal-IQ, you can update to Control-IQ technology once you have completed the Control-IQ training module and submitted the Contril-IQ update form.
Control-IQTM Technology
Predicting glucose levels 30 minutes ahead and suspending insulin, to help reduce the frequency and duration of lows.1,§
Dexcom G7 CGM Integration
The only insulin pump compatible with Dexcom G7 CGM requiring zero fingerpricks.*
Updateable Platform
Capable of remote feature updates, instead of waiting for a whole new pump!
Large, Colour Touchscreen
The t:slim X2 insulin pump was designed to be user-friendly, with an easy-to-read, easy-to-use interface.
Always read the label and use only as directed. Read the warnings available on nzmsdiabetes.co.nz/resources before purchasing. Consult your healthcare professional to see if this product is right for you.
NZMS is a Dexcom company, 2a Fisher Crescent, Mt Wellington, Auckland, 1060.
*If your glucose alerts and readings from Dexcom G7 do not match symptoms or expectations use a blood glucose meter to make diabetes treatment decisions. ^As measured by Dexcom CGM ¶ # Between the hours of 4 am to 7 am while using Control‑IQ technology. † Dexcom G7 CGM sold separately. Funded Dexcom CGM is available through Pharmac for eligible individuals, for more information visit https://pharmac.govt.nz/. § Control-IQ technology is not a substitute for active self-management of your diabetes. Control-IQ technology is only available with Dexcom G6 or G7 CGM.
1. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al. 2018;41(10):2155-2161. doi:10.2337/dc18-0771. 2. Breton MD, Kovatchev BP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23(9):601-608. doi: 10.1089/dia.2021.0097. 3. Kudva YC, Laffel LM, Brown SA, et al. Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial. Diabetes Technol Ther. 2021;23(10):673-683. doi: 10.1089/dia.2021.0089. 4. Welsh JB, et al. Comparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems.
Tandem t:slim X2 insulin pump with Control-IQ provides continuous delivery of insulin through a subcutaneously applied infusion set. The algorithm will adjust insulin delivery according to the predicted glucose when used with a compatible CGM and Tandem t:slim X2 insulin pump with Basal-IQ provides continuous delivery of insulin through a subcutaneously applied infusion set. The algorithm will stop insulin delivery according to the predictive low glucose when used with a compatible CGM.
Dexcom CGM are continuous glucose monitoring systems indicated for the management of (type 1, type 2, gestational) diabetes in people age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated.